The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets
Open accessPublished version of a preprint
Abstract
The genetic, biologic, and clinical heterogeneity of sarcomas poses a challenge for the identification of therapeutic targets, clinical research, and advancing patient care. Because there are > 100 sarcoma subtypes, in-depth genetic studies have focused on one or a few subtypes. Herein, we report a comparative genetic analysis of 2,138 sarcomas representing 45 pathological entities. This cohort is prospectively analyzed using targeted sequencing to characterize subtype-specific somatic alterations in targetable pathways, rates of whole genome doubling, mutational signatures, and subtype-agnostic genomic clusters. The most common alterations are in cell cycle control and TP53 , receptor tyrosine kinases/PI3K/RAS, and epigenetic regulators. Subtype-specific associations include TERT amplification in intimal sarcoma and SWI/SNF alterations in uterine adenosarcoma. Tumor mutational burden, while low compared to other cancers, varies between and within subtypes. This resource will improve sarcoma models, motivate studies of subtype-specific alterations, and inform investigations of genetic factors and their correlations with treatment response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite their genetic complexity, these sarcomas share genomic alterations causing PI3K/Akt/mTOR and MAPK pathway activation”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, due to the high heterogeneity of somatic mutations in osteosarcoma,14,15 the use of a tumor-agnostic MRD panel would compromise sensitivity, leading to reduced sequencing depth and overlooking unique somatic variants.”
From Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma (2024) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Self-citationSiegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071 · cited 1×
“Indeed, recent work suggests that the highest quintile of TMB within a specific cancer 405 type is associated with improved outcomes following checkpoint inhibitor therapy and, following 406 from that observation, that the TMB threshold for benefit is not absolute (49).”
BackgroundSelf-citationThe repertoire of mutational signatures in human cancer
Alexandrov, L. B., Kim, J., Haradhvala, N. J., Huang, M. N., Tian Ng, A. W., Wu, Y., Boot, A., Covington, K. R., Gordenin, D. A., Bergstrom, E. N., et al. (2020) · Nature · doi:10.1038/s41586-020-1943-3 · Cited by 3,496 · cited 1×
“480 Mutational signatures for samples with ≥ 15 synonymous and nonsynonymous single nucleotide 481 variants (SNVs) were extracted using the COSMIC v3 catalog of exome reference signatures 482 and default parameters (59) (https://github.”
MethodZehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 3×
“160 Because a pan-cancer MSK-IMPACT analysis identified TERT promoter mutations in a subset 161 of sarcomas (18), we investigated their frequency as a function of sarcoma subtype (Fig.”
BackgroundMethodSelf-citation
Cited by
The landscape of drug sensitivity and resistance in sarcoma
Shihabi, A. A., Tebon, P. J., Nguyen, H. T. L., Chantharasamee, J., Sartini, S., Davarifar, A., Jensen, A. Y., Diaz-Infante, M. B., Cox, H., Gonzalez, A. E., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.08.010 · Cited by 86
ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas
Ray-Coquard, I. L., Casali, P. G., Croce, S., Fennessy, F. M., Fischerová, D., Jones, R. L., Sanfilippo, R. G., Zapardiel, I., Amant, F. C., Blay, J., et al. (2024) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2024-005823 · Cited by 79
“40 The diagnosis of PEComa is based on morphology, and melanocytic marker expression (see Table 1).”
Self-citationBiology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options
Tlemsani, C., Larousserie, F., Percin, S. D., Audard, V., Hadjadj, D., Chen, J., Biau, D. J., Anract, P., Terris, B., Goldwasser, F., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021361 · Cited by 57
“The most extensive cohort includes 55 conventional or dedifferentiated CS and has been performed by the MSKCC-IMPACT program [28].”
MethodThe proteomic landscape of soft tissue sarcomas
Burns, J., Wilding, C. P., Krásný, L., Zhu, X., Chadha, M., Tam, Y. B., Hari, P. S., Mahalingam, A. H., Lee, A. T. J., Arthur, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39486-2 · Cited by 49
Luo, T., Fan, Z., Zeng, A., Wang, A., Pan, Y., Xu, Y., Chen, H., Chen, W., Nie, D., Lin, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202410427 · Cited by 44
Metadata
- Authors
- Nacev, B. A., Sanchez-Vega, F., Smith, S. A., Antonescu, C. R., Rosenbaum, E., Shi, H., Tang, C., Socci, N. D., Rana, S., Gularte-Mérida, R., Zehir, A., Gounder, M. M., Bowler, T. G., Luthra, A., Jadeja, B., Okada, A., Strong, J. A., Stoller, J., Chan, J. E., Chi, P., D’Angelo, S. P., Dickson, M. A., Kelly, C. M., Keohan, M. L., Movva, S., Thornton, K., Meyers, P. A., Wexler, L. H., Slotkin, E. K., Glade Bender, J. L., Shukla, N. N., Hensley, M. L., Healey, J. H., La Quaglia, M. P., Alektiar, K. M., Crago, A. M., Yoon, S. S., Untch, B. R., Chiang, S., Agaram, N. P., Hameed, M. R., Berger, M. F., Solit, D. B., Schultz, N., Ladanyi, M., Singer, S., & Tap, W. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Singer, Samuel
- Tap, William D.
- ORCID
- Nacev, Benjamin A.
- Sanchez-Vega, Francisco
- Smith, Shaleigh A.
- Antonescu, Cristina R.
- Shi, Hongyu
- Socci, Nicholas D.
- Rana, Satshil
- Gularte-Mérida, Rodrigo
- Zehir, Ahmet
- Gounder, Mrinal M.
- Luthra, Anisha
- Jadeja, Bhumika
- Chan, Jason E.
- Chi, Ping
- D’Angelo, Sandra P.
- Dickson, Mark A.
- Kelly, Ciara M.
- Keohan, Mary Louise
- Movva, Sujana
- Meyers, Paul A.
- Wexler, Leonard H.
- Slotkin, Emily K.
- Glade Bender, Julia L.
- Shukla, Neerav N.
- Hensley, Martee L.
- Healey, John H.
- Alektiar, Kaled M.
- Crago, Aimee M.
- Yoon, Sam S.
- Untch, Brian R.
- Chiang, Sarah
- Agaram, Narasimhan P.
- Hameed, Meera R.
- Berger, Michael F.
- Solit, David B.
- Schultz, Nikolaus
- Ladanyi, Marc
- Singer, Samuel
- Tap, William D.
- Venue
- Nature Communications
- Published
- 2022-06-15
- Volume
- 13
- Issue
- 1
- Pages
- 3405-3405
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC9200818
- OpenAlex
- W4282977145
- Cited by
- 232
- References
- 68
- Citations by year
- 2026: 58 · 2025: 64 · 2024: 59 · 2023: 45 · 2022: 6
- FWCI
- 28.69
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Health & Human Services | National Institutes of Health (P50 CA217694, P30 CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- soft tissue sarcoma, bone sarcoma, sarcoma subtypes, somatic alterations, therapeutic target, whole-genome duplication, mutational signatures, tumor mutational burden, TP53, receptor tyrosine kinase, epigenetic regulators, TERT amplification, intimal sarcoma, uterine adenosarcoma, genomic heterogeneity
- MeSH terms
- Bone Neoplasms, Humans, Sarcoma, Osteosarcoma, Soft Tissue Neoplasms, Genomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. https://app.cochat.ai/papers/10.1038/s41467-022-30453-x
- The paper
- Nacev, B. A., Sanchez-Vega, F., Smith, S. A., Antonescu, C. R., Rosenbaum, E., Shi, H., Tang, C., Socci, N. D., Rana, S., Gularte-Mérida, R., Zehir, A., Gounder, M. M., Bowler, T. G., Luthra, A., Jadeja, B., Okada, A., Strong, J. A., Stoller, J., Chan, J. E., . . . Tap, W. D. (2022). Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nature Communications. https://doi.org/10.1038/s41467-022-30453-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.